
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PKU Easy Microtabs Plus
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Birmingham Women's and Children's NHS Foundation Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
PKU EASY Microtabs Plus - Acceptability and Tolerance
Details : PKU Easy Microtabs Plus is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Phenylketonurias.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : PKU Easy Microtabs Plus
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Birmingham Women's and Children's NHS Foundation Trust
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nefopam HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2017
Lead Product(s) : Nefopam Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Co-Codamol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Co-Codamol is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 12, 2017
Lead Product(s) : Co-Codamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Erdosteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Recipient : Hull University Teaching Hospitals NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Erdosteine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2010
Lead Product(s) : Erdosteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Recipient : Hull University Teaching Hospitals NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
